RT Journal Article
SR Electronic
T1 COVID-19 pneumonia and clinical follow-up: results of a prospective cohort
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP PA3650
DO 10.1183/13993003.congress-2021.PA3650
VO 58
IS suppl 65
A1 Eva Ailín Vallejos
A1 Sabrina Resnik
A1 Florencia Santtia
A1 Laura Barria
A1 Federico Felder
A1 Mariano Sosa
A1 Facundo Nogueira
A1 Juan Enghelmayer
A1 Ana Putruele
A1 Carlos Luna
YR 2021
UL http://erj.ersjournals.com/content/58/suppl_65/PA3650.abstract
AB Introduction: COVID-19 pandemic has led to a rise in hospitalized patients with viral pneumonia and we are still learning about the follow-up process.Objective: To describe a cohort of hospitalized patients with COVID pneumonia and the clinical follow up once discharged.Methods: Prospective cohort study. COVID pneumonia patients from August 2020 to January 2021 were analyzed (n=72), with a standardized clinical follow-up a month after discharge. We describe clinical features, extent of pneumonia and treatment provided. We define Extent Pneumonia as an affection of ≥ 4 of 6 radiographic zones and/or 3 of 5 lobes in chest CT and compare vs Non extent pneumonia. Lastly, we describe the findings on the clinical follow-up.Results: Table 1: Cohort´s description. Table 2: Extent and Non extent pneumonia comparison. Clinical follow-up: 8(11.1%) patients persist symptomatic after discharge (4cough-3dyspnea-1anosmia). Age(yrs)59(46-72)Male(%)37(51.4)Chronic Lung Disease, total(%)Former/Actual SmokerCOPDAsthma36(50)24(33.3)5(6.9)2(2.8)Hypertension(%)26(36.1)Diabetes(%)13(18.1)Immunosuppresion(%)11(15.3)FeverCoughDyspnea56(77.8)42(58.3)40(55.6)O2 required(%)48(66.7)COVID treatment(%)Convalescent plasma + SteroidsSteroids51(70.8)37(51.4)14(19.4)Non-Extent pneumoniaExtent pneumoniap valueImmunosuppression(%)0(0)11(20.4)0.037Fever(%)9(12.5)47(65.3)0.001Dyspnea(%)6(8.3)34(47.2)0.028O2 required(%)7(9.7)41(56.9)0.004Symptom persistence2(2.8)6(8.33)0.001Conclusions: We present a thorough description of clinical data and our findings define the features associated with extent pneumonia. The clinical follow-up showed a relatively low frequency of symptom persistence.FootnotesCite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA3650.This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).